Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

An anonymous family foundation has promised to match up to $250,000 in donations for a project to restore the 1891 wrought iron Bell Road Bridge and make it a gateway into town.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Originally founded as the American arm of Germany’s Merck Group in 1891, the company has grown into a leader in the industry, ranking among the top five pharmaceutical firms by revenue.

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025 ...

40 x 50 cm. (15.7 x 19.7 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.